RxDoctor Payments Data

Richard Bale, MD

Family Medicine · Spokane, WANPI 1821100223

Payments from drug & device makers

$1,546in general payments, 2019–2025

Across 75 payments — averaging $20.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$479
  • Boehringer Ingelheim$348
  • Phathom Pharmaceuticals, Inc.$164
  • Johnson & Johnson$144
  • Novartis$97
  • Lilly USA, LLC$80
  • plus $235 from 7 others

What the payments were for

  • Food & beverage$1,546100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,546 in reported general payments places this provider in the 85th percentile of 2,275 family medicine providers in Washington.

See all family medicine providers in Washington

Medicare billing

Part B allowed, 2024
$140,814
Medicare patients
241
Services billed
1,417

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban46$49,618
JardianceEmpagliflozin23$28,195
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen372$9,606
Dexlansoprazole DrDexlansoprazole15$2,622
Zolpidem Tartrate124$2,554
Gabapentin79$2,453
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen80$2,340
Rosuvastatin Calcium117$2,107
Losartan Potassium176$1,949
Levothyroxine Sodium192$1,809
Potassium Chloride74$1,734
Atorvastatin Calcium154$1,511
Amlodipine Besylate154$1,496
Tamsulosin Hcl87$1,381
Albuterol Sulfate HfaAlbuterol Sulfate34$1,375

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$348$28,19523 claims
AbbVieSynthroid$53$67213 claims
Almatica Pharma LLCSertraline Hcl$53$44645 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,275 family medicine providers in Washington.

Other family medicine in Spokane

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →